Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, UK.
BMJ Open. 2013 Dec 18;3(12):e004348. doi: 10.1136/bmjopen-2013-004348.
Aortic stenosis (AS) is the commonest valve disorder in the developed world requiring surgery. Surgery in patients with severe asymptomatic AS remains controversial. Exercise testing can identify asymptomatic patients at increased risk of death and symptom development, but with limited specificity, especially in older adults. Cardiac MRI (CMR), including myocardial perfusion reserve (MPR) may be a novel imaging biomarker in AS.
(1) To improve risk stratification in asymptomatic patients with AS and (2) to determine whether MPR is a better predictor of outcome than exercise testing and brain natriuretic peptide (BNP).
METHOD/DESIGN: Multicentre, prospective observational study in the UK, comparing MPR with exercise testing and BNP (with blinded CMR analysis) for predicting outcome.
170 asymptomatic patients with moderate-to-severe AS, who would be considered for aortic valve replacement (AVR).
Composite of: typical symptoms necessitating referral for AVR and major adverse cardiovascular events.
FOLLOW-UP: 12-30 months (minimum 12 months).
MPR will be a better predictor of outcome than exercise testing and BNP.
ETHICS/DISSEMINATION: The study has full ethical approval and is actively recruiting patients. Data collection will be completed in November 2014 and the study results will be submitted for publication within 6 months of completion.
NCT01658345.
在发达国家,主动脉瓣狭窄(AS)是最常见的瓣膜疾病,需要手术治疗。对于无症状的重度 AS 患者,手术治疗仍存在争议。运动试验可以识别出死亡和症状发展风险增加的无症状患者,但特异性有限,尤其是在老年人中。心脏磁共振(CMR),包括心肌灌注储备(MPR),可能是 AS 的一种新的影像学生物标志物。
(1)改善无症状 AS 患者的风险分层,(2)确定 MPR 是否比运动试验和脑钠肽(BNP)更能预测预后。
方法/设计:在英国进行的多中心前瞻性观察性研究,比较 MPR 与运动试验和 BNP(CMR 分析设盲)在预测预后方面的表现。
170 例无症状、中重度 AS 患者,这些患者将被考虑行主动脉瓣置换术(AVR)。
典型症状需要转诊行 AVR 和主要不良心血管事件的复合终点。
12-30 个月(至少 12 个月)。
MPR 将比运动试验和 BNP 更能预测预后。
伦理/传播:该研究已获得完整的伦理批准,并正在积极招募患者。数据收集将于 2014 年 11 月完成,研究结果将在完成后 6 个月内提交发表。
临床试验.gov 标识符:NCT01658345。